The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Patient Recruitment and Retention Services Market (2nd Edition) by Therapeutic Areas (Cardiovascular Diseases, Oncological Disorders, Infectious Diseases, CNS Disorders, Respiratory Disorders, Hematological Disorders and Others), Patient Recruitment Steps (Pre-screening and Screening), Trial Phases (Phase I, Phase II, Phase III and Phase IV), and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    March 2021

  • Pages
    365

  • View Count
    18016

Example Insights

Patient-Recruitment-and-Retention-Services-Market-Context Patient-Recruitment-and-Retention-Services-Market-List-of-Service-Providers Patient-Recruitment-and-Retention-Services-Market-Patient-Recruitment-and-Retention-Service Patient-Recruitment-and-Retention-Services-Market-Distribution-by-Geography
Patient-Recruitment-and-Retention-Services-Market-Company-Competitiveness-Analysis Patient-Recruitment-and-Retention-Services-Market-Partnerships-and-Collaborations Patient-Recruitment-and-Retention-Services-Market-Future-Growth-Opportunities 	Patient-Recruitment-and-Retention-Services-Market-Global-Demand-for-Study-Participants
Patient-Recruitment-and-Retention-Services-Market-Distribution-by-Trial-Phase Patient-Recruitment-and-Retention-Services-Market-Insights-from-Primary    

Overview

Due to several factors, such as steady rise in global clinical trials, demand for highly specific study participants, and complex inclusion-exclusion criteria, and the challenges associated with enrolling patients in modern clinical trials, pharmaceutical companies are increasingly using the services of dedicated patient recruitment firms.

-- Chief Operations Officer, Israel-based Small-sized Patient Recruitment Firm

Clinical trials are a fundamental requirement for evaluating the safety and efficacy of novel therapeutic interventions. Owing to the involvement of several different stakeholders and given the inherent complexity of the process, these trials are prone to delays, and only 10% of the pharmacological leads that are evaluated, eventually enter the market. Clinical research is also capital intensive; it is estimated that, in the US alone, 40% of the pharma R&D budget is spent on conducting clinical trials. Moreover, there are several other challenges, including inefficiencies related to data handling, and difficulties associated with patient recruitment and retention, which further complicate the investigation of new treatment options. Experts believe that the delays in product launch, caused due to inadequate recruitment, result in an average loss of USD 8 million per day, in terms of opportunity costs, for a blockbuster drug.  Among the aforementioned areas of concern, patient recruitment is considered a major limiting factor with regards to the time required for a new drug to enter the market; in other words, trial durations are often extended on the grounds of insufficient enrolment. Current estimates indicate that 86% of registered clinical trials do not meet their intended planned enrolment deadlines. In additions, an estimated 37% of clinical research sites do not meet their respective subject accrual goals, while more than 10% fail to enrol even a single patient. Furthermore, retaining patients is also a major concern in pharmaceutical R&D; the approximate dropout rate (proportion of patients that are likely to leave a study before its designated end) across clinical studies conducted worldwide, is around 30%. 

Over the years, patient recruitment and retention strategies have evolved significantly, especially with the availability of a variety of digital data generation, management and marketing solutions. In fact, a number of modern technology-enabled offerings are now available to support various aspects of clinical research, which include patient identification and recruitment. However, not many pharmaceutical companies have the required expertise and / or resources, to develop the necessary capabilities and effectively use the aforementioned solutions. As a result, outsourcing has become a popular operating model with regards to patient recruitment and retention; several specialty service providers, with expertise and experience in this domain, are driving the growth of this upcoming segment of the healthcare market. The advantages of engaging contract service providers are numerous and enable sponsors to meet their clinical research timelines and thereby, launch respective offerings as planned. The growing complexity of clinical trials and demand for niche patient populations for studies evaluating orphan drugs / personalized medicines, have driven many big pharma players to also outsource their patient recruitment operations and are likely to prompt more developer companies to follow suit. Recently, there has been a lot of activity within the patient recruitment and retention services market, mostly focused on consolidation of affiliated capabilities, service portfolio expansions, and collaborations to extend geographical reach. Further, considering the kind of impact the COVID-19 pandemic had on on-site activities and manual processes, we are led to believe that the patient and retention services market is likely to witness significant growth in the foreseen future. 

Scope of the Report

The ‘Patient Recruitment and Retention Services Market (2nd Edition) by Therapeutic Areas (Ophthalmological Disorders, Respiratory Disorders, Dermatological Disorders, Gastrointestinal Disorders, Metabolic Disorders, CNS Disorders, Oncological Disorders, Infectious Diseases, Cardiovascular Diseases and Others), Patient Recruitment Steps (Pre-screening and Screening), Trial Phases (Phase I, Phase II, Phase III and Phase IV), and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2021-2030’ report includes an extensive study of the current scenario and future opportunities for the players providing patient enrollment and retention services. The study features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes: 

  • A detailed assessment of the current market landscape of companies offering patient recruitment and retention services, including information on over 10 types of patient outreach methods employed, types of services offered [A] patient recruitment (including pre-screening and Institutional Review Board (IRB) / Ethics Committee (EC) submission), [B] patient retention (including various strategies, such as the use of study-branded reminders, providing education and support materials, reimbursement programs, transportation programs, study-branded gifts, patient engagement web site, mobile applications to track patient engagement, patient reconnect programs and others) and [C] other associated services (including site identification and selection, study feasibility / protocol development, project management, clinical trial monitoring and other services), year of establishment, geographical location, and size of company. The chapter also covers an analysis of the geographical reach and expertise of service providers, along with details on the payment model, patient recruitment platforms / technologies used, and the various certifications / accreditations awarded by regulatory bodies.
  • An analysis of the patient recruitment and retention activity in various regions, based on the location of companies engaged in this domain, featuring schematic world map representations that highlight the key hubs across the globe.
  • An insightful 2×2 representation of the competitiveness analysis of various service providers (segregated into three peer groups based on their employee count (small (1-200 employees), mid-sized (201-500 employees) and large / very large (>500 employees)), highlighting the top players in this domain, based on their respective capabilities.
  • Detailed profiles of patient recruitment and retention service providers, featuring information on the location of their headquarters, year of establishment, patient recruitment services / platforms portfolio, recent developments and an informed future outlook.
  • An analysis of the collaborations and partnership agreements inked in this domain since 2013; it includes details of the deals focused on patient recruitment and retention, which were analyzed on the basis of year of partnership, type of partnership (service alliances, acquisitions, patient recruitment / retention agreements, joint ventures, mergers, technology licensing agreements and others), focus area, target therapeutic area, and region. It also highlights the most active players (in terms of number of partnerships). 
  • An informed estimate of the annual demand for study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.
  • A review of emerging trends in the industry, including the use of social media, mobile technologies, EHRs and RWE, to overcome the challenges associated with patient recruitment and retention.
  • A case study on regulatory landscape of patient recruitment, highlighting the regulatory process involved in patient enrollment, along with the information on regulatory guidelines, ethics committees in different countries, documents reviewed by the ethics committees (including clinical protocol, informed consent forms, investigator’s brochure and participant information), ethics committee fee and review timeline. 
  • A brief overview of patient recruitment in clinical trials focused on personalized medicines and rare diseases, highlighting the key challenges in patient enrollment, specialized patient outreach methods being used and the key players.
  • A detailed discussion on the upcoming trends (such as rise in the number of clinical trials, development of personalized medicine / orphan drugs, growing opportunities in emerging markets, increasing preference for one-stop solutions and others) in the field of patient recruitment and retention that are likely to impact the evolution of the market over the coming years.
  • A discussion on the likely impact of the ongoing COVID-19 pandemic on the patient recruitment and retention services market. In addition, it features various strategies that different companies have adopted / may adopt in order to mitigate the challenges associated with patient recruitment during the current global crisis.

One of the key objectives of the report was to estimate the existing market size and review the potential growth opportunities for patient recruitment service providers. Based on several parameters, we have provided an informed estimate of the likely evolution of this market in the short to mid-term and long term, for the period 2021-2030. In addition, we have segmented the future opportunity across [A] therapeutic areas (ophthalmological disorders, respiratory disorders, dermatological disorders, gastrointestinal disorders, metabolic disorders, CNS disorders, oncological disorders, infectious diseases, cardiovascular diseases and others), [B] patient recruitment steps (pre-screening and screening), [C] trial phases (phase I, phase II, phase III and phase IV), and [D] key geographies (North America, Europe, Asia Pacific, Middle East and Latin America, and Rest of the World). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution. 

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Simon Klaasen (Co-founder and Managing Director, Link2Trials)
  • Hagit Nof (Chief Operation Officer and Business Development, nRollmed)
  • Paul Ivsin (Managing Director, Seeker Health)

 All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players offering patient recruitment and retention services?
  • Which partnership models are commonly adopted by stakeholders engaged in this industry?
  • What are the key regulatory guidelines governing the patient recruitment in clinical trials, across various geographies?
  • What are the major market trends and driving factors that are likely to impact the growth of patient recruitment and retention services market?
  • How has the COVID-19 pandemic impacted the patient recruitment and retention services market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the patient recruitment and retention services market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to the process of patient recruitment and retention in clinical trials. It includes a detailed discussion on the different phases of clinical trials, patient recruitment and its associated challenges, various strategies used to enhance patient accrual, affiliated ethical considerations and outsourcing activity in this domain. Further, it includes a detailed discussion on the various patient recruitment services offered by different contract service providers. Additionally, the chapter features a discussion on the patient retention strategies presently being employed to prevent enrolled participants from dropping out of clinical research studies.

Chapter 4 provides an overview of the various types of patient outreach methods used by contract service providers in this domain, to identify and enroll patients in clinical trials. The chapter also highlights the various advantages and limitations of these outreach methods.
 
Chapter 5 features a detailed review of the current market landscape of companies offering patient recruitment and retention services, including an in-depth analysis based on their year of establishment, geographical location, company size, type of services offered, type of patient outreach methods, geographical reach, and the therapeutic expertise of service providers. In addition, it includes details on the payment model, patient recruitment platforms / technologies used, and the various certifications / accreditations awarded to companies, by regulatory bodies from across the world.

Chapter 6 provides an insightful competitiveness analysis of patient recruitment and retention service providers that we came across during our research. The analysis compares the service providers on the basis of various parameters, such as patient outreach methods, number of patient recruitment and retention services offered, therapeutic expertise, geographical reach and year of establishment. In the chapter, stakeholder entities have been plotted on a 2×2 matrices, having a company’s experience (based on its year of establishment) (abscissa) and Company Competitiveness (ordinate) as the two axes. 

Chapter 7 features detailed profiles of the prominent players providing patient recruitment and retention services in North America. Each company profile includes a brief overview of the company (including information on their headquarters, year of establishment, key executives and number of employees), patient recruitment services / platforms portfolio, recent developments and an informed future outlook.

Chapter 8 features detailed profiles of the prominent players providing patient recruitment and retention services in Europe. Each company profile includes a brief overview of the company (including information on their headquarters, year of establishment, key executives and number of employees), patient recruitment services / platforms portfolio, recent developments and an informed future outlook.

Chapter 9 features detailed profiles of the prominent players providing patient recruitment and retention services in Asia Pacific. Each company profile includes a brief overview of the company (including information on their headquarters, year of establishment, key executives and number of employees), patient recruitment services / platforms portfolio, recent developments and an informed future outlook.

Chapter 10 features an analysis of the various partnerships and collaborations inked amongst players in this domain, during the time period 2013-2021 (till January).  It provides a brief description on the various partnership models (service alliance, acquisition, patient recruitment / retention agreement, joint venture, merger, technology licensing agreement and other relevant types of deals) that have been adopted by stakeholders in this domain. Further, it includes analyses based on year of partnership, type of partnership, focus area, and therapeutic area, highlighting the most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. 

Chapter 11 provides a detailed overview of the prevalent trends in the patient recruitment and retention services domain, including the use of social media, mobile technologies, EHRs and RWE, to overcome the challenges associated with patient recruitment and retention in clinical research.

Chapter 12 features a detailed discussion on the upcoming opportunities (such as rise in the number of clinical trials, development of personalized medicine / orphan drugs, growing opportunities in emerging markets, increasing preference for one-stop solutions and others) in the field of patient recruitment and retention.

Chapter 13 present a case study on regulatory landscape of patient recruitment, highlighting the regulatory process involved in patient enrollment, along with the information on regulatory guidelines, ethics committees in different countries, documents reviewed by the ethics committees (including clinical protocol, informed consent forms, investigator’s brochure and participant information), ethics committee fee and review timeline. 

Chapter 14 features a brief overview of patient recruitment in clinical trials focused on personalized medicines and rare diseases, highlighting the key challenges in patient enrollment, specialized patient outreach methods and the key players.

Chapter 15 provides an informed estimate of the annual demand for study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.

Chapter 16 presents an insightful market forecast analysis, highlighting the likely growth and future potential of patient recruitment services market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of  [A] therapeutic area (ophthalmological disorders, respiratory disorders, dermatological disorders, gastrointestinal disorders, metabolic disorders, CNS disorders, oncological disorders, infectious diseases, cardiovascular diseases and others), [B] patient recruitment step (pre-screening and screening), [C] trial phase (phase I, phase II, phase III and phase IV), and [D] key geographies (North America, Europe, Asia Pacific, Middle East and Latin America, and Rest of the World).

Chapter 17 features a discussion on the likely impact of the ongoing COVID-19 pandemic on the overall patient recruitment and retention market and the initiatives undertaken by big service providers to overcome the challenges faced due to the pandemic.

Chapter 18  is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the patient recruitment and retention services market.

Chapter 19 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Simon Klaasen (Co-founder and Managing Director, Link2Trials), Hagit Nof (Chief Operation Officer and Business Development, nRollmed) and Paul Ivsin (Managing Director, Seeker Health). 

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 21 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Clinical Trials

3.3. Patient Recruitment in Clinical Trials
3.3.1. Challenges Associated with Patient Recruitment
3.3.2. Strategies to Improve Patient Recruitment
3.3.3. Ethical Considerations

3.4. Outsourcing Patient Recruitment
3.4.1. Patient Recruitment-related Services

3.5. Patient Retention
3.5.1. Patient Retention-related Services

3.6. Concluding Remarks

4. PATIENT OUTREACH METHODS
4.1. Chapter Overview
4.2. Patient Outreach Methods
4.2.1. Traditional Patient Outreach Methods
4.2.1.1. Physician Referrals
4.2.1.2. Television
4.2.1.3. Radio
4.2.1.4. Print Media (Newspaper, Flyers, Brochures and Posters)
4.2.1.5. Direct Mail Campaign
4.2.1.6. Cold Call / Call Centre
4.2.1.7. Advantages and Limitations of Traditional Media

4.2.2. Emerging Patient Outreach Methods
4.2.2.1. Social Media
4.2.2.1.1. Geo-Social Media
4.2.2.1.2. Social Networking Websites
4.2.2.1.3. Advantages and Limitations of Social Media

4.2.2.2. Mobile / Software Applications
4.2.2.3. Patient Networks
4.2.2.4. Patient Advocacy Groups
4.2.2.5. Electronic Medical Records (EMRs) / Electronic Health Records (EHRs) and Other Health Registries
4.2.2.6. Search Engine Marketing / Artificial Intelligence-based Marketing
4.2.2.7. Over-the-top (OTT) Media Platforms
4.2.2.8. Indication Specific Events (for Patients)

4.2.3. Best Practices / Recommendations for Patient Outreach

5. COMPETITIVE MARKET LANDSCAPE OF PATIENT RECRUITMENT AND RETENTION SERVICE PROVIDERS
5.1. Chapter Overview
5.2. Patient Recruitment and Retention Service Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment 
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Patient Recruitment and Retention Services Offered
5.2.5. Analysis by Patient Outreach Methods
5.2.6. Analysis by Patient Recruitment Associated Services
5.2.7. Analysis by Patient Retention Methods
5.2.8. Analysis by Geographical Reach
5.2.9. Analysis by Therapeutic Expertise
5.2.10. Information on Payment Model, Recruitment Technology / Platform, and Regulatory Approval / Certification / Compliance Status

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Patient Recruitment and Retention Service Providers: Company Competitiveness Analysis
6.4.1. Competitiveness Analysis: Small Companies
6.4.2. Competitiveness Analysis: Mid-Sized Companies
6.4.3. Competitiveness Analysis: Large / Very Large Companies

7. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Acurian
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Patient Recruitment and Retention Services
7.2.4. Recent Developments and Future Outlook

7.3. BBK Worldwide
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Patient Recruitment and Retention Services
7.3.4. Recent Developments and Future Outlook

7.4. Bright Pharmaceutical Services
7.4.1. Company Overview
7.4.2. Patient Recruitment and Retention Services
7.4.3. Recent Developments and Future Outlook

7.5. ClinEdge
7.5.1. Company Overview
7.5.2. Patient Recruitment and Retention Services
7.5.3. Recent Developments and Future Outlook

7.6. CSSi
7.6.1. Company Overview
7.6.2. Patient Recruitment and Retention Services
7.6.3. Recent Developments and Future Outlook

7.7. CTM
7.7.1. Company Overview
7.7.2. Financial Information
7.7.3. Patient Recruitment and Retention Services
7.7.4. Recent Developments and Future Outlook

7.8. Evolution Research Group (ERG)
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. Patient Recruitment and Retention Services
7.8.4. Recent Developments and Future Outlook

7.9. Integrated Clinical Trial Services (ICTS)
7.9.1. Company Overview
7.9.2. Patient Recruitment and Retention Services
7.9.3. Recent Developments and Future Outlook

7.10. MMG
7.10.1. Company Overview
7.10.2. Patient Recruitment and Retention Services
7.10.3. Recent Developments and Future Outlook

7.11. Veristat
7.11.1. Company Overview
7.11.2. Financial Information
7.11.3. Patient Recruitment and Retention Services
7.11.4. Recent Developments and Future Outlook

7.12. WCCT Global
7.12.1. Company Overview
7.12.2. Financial Information
7.12.3. Patient Recruitment and Retention Services
7.12.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN EUROPE
8.1. Chapter Overview
8.2. Antidote
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Patient Requirement and Retention Services
8.2.4. Recent Developments and Future Outlook

8.3. Clinical Accelerator
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Patient Recruitment and Retention Services
8.3.4. Recent Developments and Future Outlook

8.4. Fidelis Research
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Patient Recruitment and Retention Services
8.4.4. Recent Developments and Future Outlook

8.5. Ignite Data
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Patient Recruitment and Patient Retention
8.5.4. Recent Developments and Future Outlook

8.6. Polaris BioPharma Consulting
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Patient Recruitment and Retention Services
8.6.4. Recent Developments and Future Outlook

8.7. Raremark
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Patient Recruitment and Retention Services
8.7.4. Recent Developments and Future Outlook

8.8. Trialbee
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Patient Recruitment and Retention Services
8.8.4. Recent Developments and Future Outlook

9. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN ASIA PACIFIC
9.1. Chapter Overview
9.2. Clinrol
9.2.1. Company Overview
9.2.2. Patient Recruitment and Retention Services
9.2.3. Future Outlook

9.3. CROee
9.3.1. Company Overview
9.3.2. Patient Recruitment and Retention Services
9.3.3. Recent Developments and Future Outlook

9.4. Gitzo Medical Technology
9.4.1. Company Overview
9.4.2. Patient Recruitment and Retention Services
9.4.3. Recent Developments and Future Outlook

9.5. Pacific Grove
9.5.1. Company Overview
9.5.2. Patient Recruitment and Retention Services
9.5.3. Recent Developments and Future Outlook

9.6. TrialWire
9.6.1. Company Overview
9.6.2. Patient Recruitment and Retention Services
9.6.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Patient Recruitment and Retention Services: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Focus Area
10.3.5. Analysis by Year of Partnership and Focus Area
10.3.6. Analysis by Therapeutic Area
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Geographical Analysis
10.3.8.1. Region-wise Distribution
10.3.8.2. Country-wise Distribution

11. RECENT TRENDS IN PATIENT RECRUITMENT AND RETENTION
11.1. Chapter Overview
11.1.1. Campaigning on Social Media to Accelerate Patient Recruitment in Clinical Trials
11.1.2. Adoption of Mobile Technologies for Patient Recruitment and Retention
11.1.3. Use of EHR Data to Improve Patient Recruitment Rates
11.1.4. Use of Other Real-World Data Sources to Overcome Existing Enrolment-related Challenges
11.1.5. Use of Artificial Intelligence to Improve Patient Selection
11.1.6. Increase in Adoption of the Virtual Trial Model During the COVID-19 Pandemic
11.1.7. Growing Focus on Conducting Clinical Research in Emerging Markets

12. FUTURE GROWTH OPPORTUNITIES IN PATIENT RECRUITMENT
12.1. Chapter Overview
12.1.1. Continuous Rise in the Number of Global Clinical Trials
12.1.2. Rising Demand for Orphan Drugs and Personalized Medicine
12.1.3. Increase in Offshoring Clinical Development Activity to Emerging Regions
12.1.4. Availability of Service Providers Offering One-Stop-Solutions
12.1.5. Stringent Regulations and Complex Study Protocols Prompting More Outsourcing
12.1.6. Impact of the COVID-19 Pandemic on Clinical Research Activity
12.1.7. Technological Advances in Clinical Trial Conduct

13. CASE STUDY: REGULATORY LANDSCAPE OF PATIENT RECRUITMENT
13.1. Chapter Overview
13.2. Regulatory Framework of Patient Recruitment
13.3. Regulations Involved in Patient Recruitment
13.3.1. ICH-GCP Guidelines
13.3.2. Declaration of Helsinki
13.3.3. General Data Privacy Regulation (GDPR)
13.3.4. Health Insurance Portability and Accountability Act (HIPAA)

14. PATIENT RECRUITMENT IN TRIALS FOCUSED ON PERSONALIZED MEDICINE AND RARE DISEASES
14.1. Chapter Overview
14.2. Clinical Trials Focused on Personalized Medicine and Rare Diseases
14.2.1. Key Challenges
14.2.2. Specialized Patient Outreach Methods
14.2.3. Key Players

15. ANALYSIS OF DEMAND FOR CLINICAL TRIAL PARTICIPANTS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Clinical Trial Analysis: Analysis by Enrolled Patient Population
15.3.1. Analysis by Trial Registration Year
15.3.2. Analysis by Trial Phase
15.3.3. Analysis by Trial Registration Year and Trial Phase
15.3.4. Analysis by Target Patient Segment
15.3.5. Analysis by Trial Registration Year and Target Patient Segment

15.4. Global Demand for Clinical Trial Participants: Analysis by Enrolled Patient Population
15.4.1. Demand by Trial Phase
15.4.2. Demand by Therapeutic Area
15.4.3. Geographical Demand by Enrolled Patient Population

15.5. Concluding Remarks

16. MARKET SIZING AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Overall Patient Recruitment Services Market, 2021-2030
16.4. Patient Recruitment Services Market, 2021-2030: Distribution by Therapeutic Area
16.5. Patient Recruitment Services Market, 2021-2030: Distribution by Patient Recruitment Steps
16.6. Patient Recruitment Services Market, 2021-2030: Distribution by Trial Phase
16.7. Patient Recruitment Services Market, 2021-2030: Distribution by Geography
16.7.1. Patient Recruitment Services Market, 2021-2030: Market Attractiveness Analysis by Country

16.7.2. Patient Recruitment Services Market in North America, 2021-2030
16.7.2.1. Patient Recruitment Services Market in the US, 2021-2030: Distribution by Trial Phase
16.7.2.2. Patient Recruitment Services Market in the US, 2021-2030: Distribution by Therapeutic Area
16.7.2.3. Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Trial Phase
16.7.2.4. Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Therapeutic Area

16.7.3. Patient Recruitment Services Market in Europe, 2021-2030
16.7.3.1. Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Trial Phase
16.7.3.2. Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Therapeutic Area
16.7.3.3. Patient Recruitment Services Market in France, 2021-2030: Distribution by Trial Phase
16.7.3.4. Patient Recruitment Services Market in France, 2021-2030: Distribution by Therapeutic Area
16.7.3.5. Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Trial Phase
16.7.3.6. Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Therapeutic Area
16.7.3.7. Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Trial Phase
16.7.3.8. Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Therapeutic Area
16.7.3.9. Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Trial Phase
16.7.3.10. Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Therapeutic Area
16.7.3.11. Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Trial Phase
16.7.3.12. Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Therapeutic Area

16.7.4. Patient Recruitment Services Market in Asia Pacific, 2021-2030
16.7.4.1. Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Trial Phase
16.7.4.2. Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Therapeutic Area
16.7.4.3. Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Trial Phase
16.7.4.4. Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Therapeutic Area
16.7.4.5. Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Trial Phase
16.7.4.6. Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Therapeutic Area
16.7.4.7. Patient Recruitment Services Market in China, 2021-2030: Distribution by Trial Phase
16.7.4.8. Patient Recruitment Services Market in China, 2021-2030: Distribution by Therapeutic Area
16.7.4.9. Patient Recruitment Services Market in India, 2021-2030: Distribution by Trial Phase
16.7.4.10. Patient Recruitment Services Market in India, 2021-2030: Distribution by Therapeutic Area

16.7.5 Patient Recruitment Services Market in Latin America, 2021-2030
16.7.5.1. Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Trial Phase
16.7.5.2. Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Therapeutic Area

16.7.6. Patient Recruitment Services Market in MENA, 2021-2030
16.7.6.1. Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Trial Phase
16.7.6.2. Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Therapeutic Area

16.7.7. Patient Recruitment Services Market in Rest of the World, 2021-2030
16.7.7.1. Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Trial Phase
16.7.7.2. Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Therapeutic Area

17. IMPACT OF THE COVID-19 PANDEMIC ON PATIENT RECRUITMENT SERVICES MARKET
17.1. Chapter Overview
17.2. Impact of COVID-19 Pandemic on Clinical Trials
17.2.1. Impact on Future Opportunity Related to Patient Recruitment Services
17.2.2. Initiatives Undertaken by Key Patient Recruitment and Retention Service Providers
17.2.2.1. Trialspark
17.2.2.2. BBK Worldwide
17.2.2.3. Clariness
17.2.2.4. CSSi
17.2.2.5. IQVIA
17.3. Key Strategies to Mitigate Challenges Associated with Patient Recruitment and Retention

18. CONCLUDING REMARKS

19. INTERVIEW TRANSCRIPTS
19.1. Chapter Overview
19.2. Link2Trials
19.2.1. Company Snapshot
19.2.2. Interview Transcript: Simon Klaasen, Co-founder and Managing Director

19.3. nRollmed
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Hagit Nof, Chief Operation Officer and Business Development Officer

19.4. Seeker Health
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Paul Ivsin, Managing Director

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Factors Contributing to Clinical Trial Cost
Figure 3.2 The Patient Recruitment Process
Figure 3.3 Factors Influencing Participation in Clinical Trials
Figure 3.4 Reasons for Patient Dropouts from Clinical Studies
Figure 4.1 Patient Outreach: Advantages and Limitations of Traditional Patient Outreach Methods
Figure 4.2 Patient Outreach: Advantages and Limitations of Social Media
Figure 5.1 Patient Recruitment and Retention Service Providers: Distribution by Year of Establishment
Figure 5.2 Patient Recruitment and Retention Service Providers: Distribution by Company Size
Figure 5.3 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters
Figure 5.4 Patient Recruitment and Retention Service Providers: Distribution by Company Size and Location of Headquarters
Figure 5.5 Patient Recruitment and Retention Service Providers: Distribution by Type of Service(s) Offered
Figure 5.6 Patient Recruitment and Retention Service Providers: Distribution by Type of Patient Outreach Method(s)
Figure 5.7 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Outreach Methods Offered
Figure 5.8 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment Associated Service(s) Offered
Figure 5.9 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Recruitment Associated Services Offered
Figure 5.10 Patient Recruitment and Retention Service Providers: Distribution by Patient Retention Method(s) Used
Figure 5.11 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Retention Methods
Figure 5.12 Patient Recruitment and Retention Service Providers: Distribution by Geographical Reach
Figure 5.13 Patient Recruitment and Retention Service Providers: Distribution by Therapeutic Expertise
Figure 6.1 Company Competitiveness Analysis: Small Players
Figure 6.2 Company Competitiveness Analysis: Mid-Sized Players
Figure 6.3 Company Competitiveness Analysis: Large / Very Large Players
Figure 7.1 Acurian: Innovative Tools / Approaches for Patient Enrollment
Figure 7.2 BBK Worldwide: Service Portfolio
Figure 7.3 Bright Pharmaceutical Services: Service Portfolio
Figure 7.4 ClinEdge: Service Portfolio
Figure 7.5 CSSi: Patient Recruitment and Retention Capabilities
Figure 7.6 CSSi: Study Branding Strategies
Figure 7.7 CTM: Patient Recruitment Process
Figure 7.8 CTM: Outreach Methods Used for Patient Recruitment
Figure 7.9 CTM: Technologies Used for Patient Recruitment and Retention
Figure 8.1 Antidote: Service Portfolio
Figure 8.2 Antidote Base: Patient Recruitment Process
Figure 8.3 Clinical Accelerator: Service Portfolio
Figure 8.4 FIDELIS RESEARCH: Service Portfolio
Figure 8.5 Ignite Data: Patient Recruitment and Call-Screening Process
Figure 8.6 Ignite Data: Patient Recruitment Strategies
Figure 8.7 Polaris BioPharma Consulting: Core Capabilities
Figure 8.8 Polaris BioPharma Consulting: Service Portfolio
Figure 8.9 Raremark: Service Portfolio
Figure 8.10 Raremark: Local Support Divisions
Figure 8.11 Trialbee: Patient Recruitment Process
Figure 9.1 Clinrol: Patient Recruitment Process
Figure 9.2 CROee: Service Portfolio
Figure 9.3 Pacific Grove: Business Divisions
Figure 9.4 Pacific Grove: Patient Enrollment Process
Figure 9.5 TrialWire: Patient Recruitment Process
Figure 9.6 TrialWire: Rapid Recruit Platform
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Distribution, 2013-2021 (till January)
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2013-2021 (till January)
Figure 10.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 10.5 Partnerships and Collaborations: Distribution by Year of Partnership and Focus Area
Figure 10.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.7 Most Active Players: Analysis by Number of Partnerships
Figure 10.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.9 Partnerships and Collaborations: Country-wise Distribution
Figure 11.1 Recent Trends in Patient Recruitment and Retention
Figure 12.1 Patient Recruitment Services Market: Future Growth Opportunities
Figure 12.2 Number of Global Clinical Trials Registered by Year, 2000-2020
Figure 12.3 Evolution of Clinical Trial Regulations in the US
Figure 13.1 Patient Recruitment Regulatory Pathway
Figure 13.2 Regulatory Guidelines Involved in Patient Recruitment
Figure 14.1 Key Challenges in Patient Enrollment in Trials Focused on Personalized Medicines
Figure 14.2 Key Challenges in Patient Enrollment in Trials Focused on Rare Diseases
Figure 14.3 Specialized Patient Outreach Methods
Figure 15.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 15.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 15.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Figure 15.4 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 15.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Patient Segment
Figure 15.6 Global Demand for Clinical Trial Participants: Distribution by Trial Phase
Figure 15.7 Global Demand for Clinical Trial Participants: Distribution by Therapeutic Area
Figure 15.8 Global Demand for Clinical Trial Participants: Distribution by Region
Figure 16.1 Overall Patient Recruitment Services Market, 2021-2030 (USD Billion)
Figure 16.2 Patient Recruitment Services Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.3 Patient Recruitment Services Market, 2021-2030: Distribution by Patient Recruitment Steps (USD Million)
Figure 16.4 Patient Recruitment Services Market, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.5 Patient Recruitment Services Market, 2021-2030: Distribution by Geography (USD Million)
Figure 16.6 Patient Recruitment Services Market, 2021 and 2030: Market Attractiveness Analysis by Country
Figure 16.7 Patient Recruitment Services Market in North America, 2021-2030 (USD Million)
Figure 16.8 Patient Recruitment Services Market in the US, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.9 Patient Recruitment Services Market in the US, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.10 Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.11 Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Therapeutic Area (USD Billion)
Figure 16.12 Patient Recruitment Services Market in Europe, 2021-2030 (USD Million)
Figure 16.13 Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.14 Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.15 Patient Recruitment Services Market in France, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.16 Patient Recruitment Services Market in France, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.17 Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.18 Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.19 Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.20 Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.21 Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.22 Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.23 Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.24 Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.25 Patient Recruitment Services Market in Asia Pacific, 2021-2030 (USD Million)
Figure 16.26 Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.27 Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.28 Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.29 Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.30 Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.31 Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.32 Patient Recruitment Services Market in China, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.33 Patient Recruitment Services Market in China, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.34 Patient Recruitment Services Market in India, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.35 Patient Recruitment Services Market in India, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.36 Patient Recruitment Services Market in Latin America, 2021-2030 (USD Million)
Figure 16.37 Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.38 Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.39 Patient Recruitment Services Market in MENA, 2021-2030 (USD Million)
Figure 16.40 Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.41 Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.42 Patient Recruitment Services Market in Rest of the World, 2021-2030 (USD Million)
Figure 16.43 Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Trial Phase (USD Million)
Figure 16.44 Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 17.1 Patient Recruitment Services Market, 2021-2030: COVID Impact Scenario (USD Billion)
Figure 18.1 Concluding Remarks: Overall Market Landscape

List Of Tables

Table 3.1 Characteristic Features of Clinical Trial Phases
Table 4.1 Traditional and Emerging Patient Outreach Methods
Table 5.1 List of Patient Recruitment and Retention Service Providers
Table 5.2 Patient Recruitment and Retention Service Providers: Information on Patient Outreach Methods
Table 5.3 Patient Recruitment and Retention Service Providers: Information on Type of Patient Recruitment Service(s) Offered
Table 5.4 Patient Recruitment and Retention Service Providers: Information on Patient Retention Method(s) Used
Table 5.5 Patient Recruitment and Retention Service Providers: Information on Geographical Reach
Table 5.6 Patient Recruitment and Retention Service Providers: Information on Therapeutic Expertise
Table 5.7 Patient Recruitment and Retention Service Providers: Information on Payment Model, Recruitment Technology / Platform, and Regulatory Approval / Certification / Compliance Status
Table 7.1 Leading Patient Recruitment Service Providers in North America
Table 7.2 Acurian: Company Overview
Table 7.3 Acurian: Recent Developments and Future Outlook
Table 7.4 BBK Worldwide: Company Overview
Table 7.5 BBK Worldwide: Recent Developments and Future Outlook
Table 7.6 Bright Pharmaceutical Services: Company Overview
Table 7.7 Bright Pharmaceutical Services: Recent Developments and Future Outlook
Table 7.8 ClinEdge: Company Snapshot
Table 7.9 ClinEdge: Recent Developments and Future Outlook
Table 7.10 CSSi: Company Snapshot
Table 7.11 CSSi: Recent Developments and Future Outlook
Table 7.12 CTM: Company Snapshot
Table 7.13 CTM: Recent Developments and Future Outlook
Table 7.14 Evolution Research Group: Company Snapshot
Table 7.15 Evolution Research Group: Recent Developments and Future Outlook
Table 7.16 Integrated Clinical Trial Services: Company Snapshot
Table 7.17 Integrated Clinical Trial Services: Recent Developments and Future Outlook
Table 7.18 MMG: Company Snapshot
Table 7.19 MMG: Recent Developments and Future Outlook
Table 7.20 Veristat: Company Snapshot
Table 7.21 Veristat: Recent Developments and Future Outlook
Table 7.22 WCCT Global: Company Snapshot
Table 7.23 WCCT Global: Recent Developments and Future Outlook
Table 8.1 Leading Patient Recruitment Service Providers in Europe
Table 8.2 Antidote: Company Snapshot
Table 8.3 Antidote: Funding
Table 8.4 Antidote: Recent Developments and Future Outlook
Table 8.5 Clinical Accelerator: Company Snapshot
Table 8.6 Clinical Accelerator: Recent Developments and Future Outlook
Table 8.7 FIDELIS RESEARCH Company Snapshot
Table 8.8 Fidelis Research: Recent Developments and Future Outlook
Table 8.9 Ignite Data: Company Snapshot
Table 8.10 Ignite Data: Recent Developments and Future Outlook
Table 8.11 Polaris BioPharma Consulting: Company Snapshot
Table 8.12 Polaris BioPharma Consulting: Recent Developments and Future Outlook
Table 8.13 Raremark: Company Snapshot
Table 8.14 Raremark: Recent Developments and Future Outlook
Table 8.15 Trialbee: Company Snapshot
Table 8.16 Trialbee: Funding
Table 8.17 Trialbee: Recent Developments and Future Outlook
Table 9.1 Leading Patient Recruitment Service Providers in Asia Pacific
Table 9.2 Clinrol: Company Snapshot
Table 9.3 Clinrol: Recent Developments and Future Outlook
Table 9.4 CROee: Company Snapshot
Table 9.5 CROee: Recent Developments and Future Outlook
Table 9.6 Gitzo Pharmaceuticals Company Snapshot
Table 9.7 Gitzo Pharmaceuticals : Recent Developments and Future Outlook
Table 9.8 Pacific Grove: Company Snapshot
Table 9.9 Pacific Grove: Recent Developments and Future Outlook
Table 9.10 TrialWire: Company Snapshot
Table 9.11 Trial Wire: Recent Developments and Future Outlook
Table 10.1 Patient Recruitment and Retention Services: Partnerships and Collaborations, 2013-2021 (till January)
Table 14.1 Patient Recruitment Service Providers for Trials Focused on Personalized Medicines and Rare Diseases
Table 19.1 Link2Trials: Company Snapshot
Table 19.2 nRollmed: Company Snapshot
Table 19.3 Seeker Health: Company Snapshot
Table 20.1 Patient Recruitment and Retention Service Providers: Distribution by Year of Establishment
Table 20.2 Patient Recruitment and Retention Service Providers: Distribution by Company Size
Table 20.3 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters
Table 20.4 Patient Recruitment and Retention Service Providers: Distribution by Type of Service(s) Offered
Table 20.5 Patient Recruitment and Retention Service Providers: Distribution by Type of Patient Outreach Method(s)
Table 20.6 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Outreach Methods Offered
Table 20.7 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment Associated Service(s) Offered
Table 20.8 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Recruitment Associated Services Offered
Table 20.9 Patient Recruitment and Retention Service Providers: Distribution by Patient Retention Method(s) Used
Table 20.10 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Retention Methods
Table 20.11 Patient Recruitment and Retention Service Providers: Distribution by Geographical Reach
Table 20.12 Patient Recruitment and Retention Service Providers: Distribution by Therapeutic Expertise
Table 20.13 Partnerships and Collaborations: Cumulative Year-wise Distribution, 2013-2021 (till January)
Table 20.14 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.15 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 20.16 Partnerships and Collaborations: Distribution by Focus Area
Table 20.17 Partnerships and Collaborations: Distribution by Year of Partnership and Focus Area
Table 20.18 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 20.19 Most Active Players: Analysis by Number of Partnerships
Table 20.20 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 20.21 Partnerships and Collaborations: Country-wise Distribution
Table 20.22 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 20.23 Clinical Trial Analysis: Distribution by Trial Phase
Table 20.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Table 20.25 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 20.26 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Patient Segment
Table 20.27 Global Demand for Clinical Trial Participants: Distribution by Trial Phase
Table 20.28 Global Demand for Clinical Trial Participants: Distribution by Therapeutic Area
Table 20.29 Global Demand for Clinical Trial Participants: Distribution by Region
Table 20.30 Overall Patient Recruitment Services Market, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.31 Patient Recruitment Services Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.32 Patient Recruitment Services Market, 2021-2030: Distribution by Patient Recruitment Steps (USD Million)
Table 20.33 Patient Recruitment Services Market, 2021-2030: Distribution by Trial Phase, (USD Million)
Table 20.34 Patient Recruitment Services Market, 2021-2030: Distribution by Geography (USD Million)
Table 20.35 Patient Recruitment Services Market, 2021 and 2030: Market Attractiveness Analysis by Country
Table 20.36 Patient Recruitment Services Market in North America, 2021-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.37 Patient Recruitment Services Market in the US, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.38 Patient Recruitment Services Market in the US, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.39 Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.40 Patient Recruitment Services Market in Canada, 2021-2030: Distribution by Therapeutic Area (USD Billion)
Table 20.41 Patient Recruitment Services Market in Europe, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
Table 20.42 Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.43 Patient Recruitment Services Market in Germany, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.44 Patient Recruitment Services Market in France, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.45 Patient Recruitment Services Market in France, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.46 Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.47 Patient Recruitment Services Market in the UK, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.48 Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.49 Patient Recruitment Services Market in Italy, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.50 Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.51 Patient Recruitment Services Market in Spain, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.52 Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.53 Patient Recruitment Services Market in Rest of Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.54 Patient Recruitment Services Market in Asia Pacific, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
Table 20.55 Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.56 Patient Recruitment Services Market in Japan, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.57 Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.58 Patient Recruitment Services Market in South Korea, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.59 Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.60 Patient Recruitment Services Market in Australia, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.61 Patient Recruitment Services Market in China, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.62 Patient Recruitment Services Market in China, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.63 Patient Recruitment Services Market in India, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.64 Patient Recruitment Services Market in India, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.65 Patient Recruitment Services Market in Latin America, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
Table 20.66 Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.67 Patient Recruitment Services Market in Latin America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.68 Patient Recruitment Services Market in MENA, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
Table 20.69 Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.70 Patient Recruitment Services Market in MENA, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.71 Patient Recruitment Services Market in Rest of the World, 2021-2030, Conservative, Base and Optimistic Scenario, (USD Million)
Table 20.72 Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Trial Phase (USD Million)
Table 20.73 Patient Recruitment Services Market in Rest of the World, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 20.74 Patient Recruitment Services Market, 2021-2030: COVID Impact Scenario (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in this report.

  1.     23andMe
  2.     3H Medi Solution
  3.     Abnex 
  4.     Academic Network
  5.     Accel Trial Connections Network
  6.     Access Clinical Research
  7.     Accurate Clinical Research
  8.     Acurian
  9.     Addario Lung Cancer Foundation
  10.     Addario Lung Cancer Medical Institute 
  11.     Adult Medicine
  12.     Advanced Clinical
  13.     AiCure
  14.     Alkemy Partners
  15.     Alleco Research 
  16.     Alliance Community Healthcare
  17.     Allscripts
  18.     American Liver Foundation
  19.     American Society of Clinical Oncology
  20.     Amgen
  21.     Anteris Bio
  22.     Antidote
  23.     ApotheCom
  24.     Apptomics
  25.     AQLANE Medical
  26.     Arden and Schmidt
  27.     AstraZeneca
  28.     ATLAS Medical Services
  29.     AutoCruitment
  30.     AXELLE Group
  31.     Axiom Accelerated Patient Recruitment
  32.     BBK Worldwide
  33.     BIAPharm 
  34.     Bioclinica
  35.     BIOMAPAS
  36.     Bio-Optronics
  37.     BioScript Solutions
  38.     Blue Chip Patient Recruitment (BCPR)
  39.     Blueprint Clinical
  40.     BlueTheory Clinical Trials
  41.     BMC Group
  42.     Box
  43.     Bridge Clinical Research
  44.     Bright Pharmaceutical Services
  45.     Buzzreach 
  46.     C & C Clinical
  47.     Canadian Institute for Medical Advancement (CIMA)
  48.     Capsule Communications
  49.     CaringKind
  50.     CarthagoPharma
  51.     CCBR-SYNARC 
  52.     CCT Research
  53.     Center for Women Health
  54.     Center Point Clinical Services
  55.     Centricity Health
  56.     Chandler Chicco Agency (CCA)
  57.     Chase Medical Research
  58.     Cinven
  59.     Circuit Clinical
  60.     Clariness
  61.     Clinart MENA
  62.     ClinEdge
  63.     Clinerion
  64.     Clinical Accelerator
  65.     Clinical Ambassador
  66.     Clinical List America
  67.     Clinical Trial
  68.     Clinical Trial Connect (CTC)
  69.     Clinical Trial Marketing Communications (CTMC)
  70.     Clinical Trial Networking (CT-N)
  71.     Clinical Trials Center
  72.     ClinicalConnection
  73.     Clinically Media
  74.     ClinIntel
  75.     CliniSpan Health
  76.     Clinrol
  77.     Clinspire Research
  78.     Clintec
  79.     Clintract 
  80.     Clinverse
  81.     CMX Research
  82.     Compass Research
  83.     Continuum Clinical 
  84.     CPS Research
  85.     CROee
  86.     CSSi
  87.     CSSi LifeSciences
  88.     CTC North
  89.     CTM
  90.     CUBRC
  91.     Cytespace
  92.     DAC Patient Recruitment Services
  93.     Datavant
  94.     DAVA Oncology
  95.     Discovery Clinical Trials
  96.     DrFirst
  97.     Eastern Medical
  98.     Effectus CTR
  99.     Egeen
  100. Elligo Health Research
  101. EmergingMed 
  102. eNre
  103. ePatientFinder 
  104. eStudySite
  105. European Organisation for Research and Treatment of Cancer (EORTC) 
  106. EVERSANA
  107. Evolution Research Group
  108. Evrima Technologies
  109. FDAMap
  110. FIDELIS RESEARCH
  111. Flatiron Health
  112. Foundation Medicine
  113. Friends of Cancer Research (Friends)
  114. Gaea
  115. Galen Patient Recruitment
  116. GCP Clinical Studies
  117. Genentech
  118. Gitzo Pharmaceuticals 
  119. Global Clinical Trials
  120. Global Perspectives
  121. Greater Gift
  122. Guidestar Research
  123. HCXP
  124. Healthcare Communications Group
  125. Healthjump
  126. HealthStar Physicians
  127. HealthVerity
  128. Heron Therapeutics
  129. Ignite Data
  130. Illingworth Research Group
  131. IMS Health
  132. Innovaderm Research
  133. Innovative Trials
  134. Inspire
  135. Institute of Clinical Research in India (ICRI)
  136. Integrated Clinical Trial Services (ICTS)
  137. Invicro
  138. iPatientAxis
  139. IQVIA
  140. IRM
  141. IVR Clinical Concepts
  142. IZI Medical
  143. J Trotter Research & Consulting (JTRC) 
  144. Jack Nathan Health
  145. JLL Partners
  146. Klick Health
  147. Komplett Clinical Research
  148. LabCorp Diagnostics
  149. Latium Enterprises
  150. LeadSlinger
  151. Limbix
  152. Linden Capital Partners
  153. Linical
  154. Linical Americas
  155. Link2Trials
  156. LiveRamp
  157. Lyft
  158. Medical Research South
  159. Medici Group
  160. Medidata
  161. Melanoma Research Alliance
  162. Miami Research Associates
  163. MMG
  164. Mondosano
  165. Mundipharma Research
  166. Muscular Dystrophy Association (MDA)
  167. National Cancer Institute
  168. Newton Clinical Research
  169. Noom
  170. Northumbria Healthcare
  171. nRollmed
  172. O4 Research
  173. One Research
  174. OptimizeRx
  175. Orphan Reach
  176. Orphanos
  177. Osaka International Cancer Institute
  178. Pacific Grove 
  179. Panacea Patient Recruitment
  180. Parallel 6 
  181. Parexel
  182. Patient Enrollment Advisors 
  183. PatientPoint
  184. Patient RM
  185. PatientCentra
  186. PatientEvolution
  187. Patients Direct
  188. Patiro
  189. Pepgra
  190. Pfizer
  191. PharmaCentra
  192. Pharmaceutical Product Development (PPD)
  193. Pharm-Olam 
  194. phaware.global 
  195. Pivotal Patient Journey,
  196. Polaris Biopharma Consulting
  197. Practice Fusion
  198. Praxis Communications 
  199. PRC Clinical
  200. Profil
  201. Prominis Medical Services
  202. Protenium Clinical Research
  203. PWNHealth
  204. QPS
  205. Radiant Research
  206. Raremark
  207. RealTime Software Solutions
  208. Red Maple Trials
  209. RemediumOne 
  210. Remedy Health Media
  211. Rep Network
  212. RESolutions
  213. Richmond Pharmacology
  214. Riverside Medical Group 
  215. Roche
  216. Roswell Park Comprehensive Cancer Center
  217. S4 Research
  218. Sanguine Biosciences
  219. Seeker Health
  220. Signify Health
  221. Sinque Labs
  222. SitePartner
  223. SMO Clinical Research (SMO-India)
  224. SMO Clinplus
  225. Society for Clinical Research Sites
  226. Spectrum Clinical Research
  227. Splash Clinical 
  228. STARR Coalition 
  229. SubjectWell
  230. SWOG Cancer Research
  231. Syneos Health
  232. Synexus
  233. TFS
  234. The Christie NHS Foundation Trust
  235. The Foundation for the National Institutes of Health (FNIH)
  236. The Patient Recruiting Agency (TPRA)
  237. Patient Recruitment Consultancy
  238. ThreeWire
  239. Topstone Research
  240. Total Clinical Trial Management
  241. TrialBee
  242. Trialfacts
  243. TrialJoin
  244. TrialSpark
  245. TrialWire 
  246. TriNetX
  247. United BioSource 
  248. University of Exeter
  249. Unnamed Pharma Company
  250. Velocity Clinical Research
  251. Veristat
  252. Vineti
  253. Viomedo
  254. VisibilityRx 
  255. Vizae Clinical Trial Management
  256. WCCT Global
  257. WCG PatientWise
  258. Wefight
  259. Western Washington Medical Group
  260. WIRB-Copernicus Group
  261. WorldQuant Predictive
  262. Worldwide Clinical Trials
  263. X Factor 
  264. Xcene Research

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com